To dissect the anti‐tumor effect of STK24 deficiency in CT26 cells, we inoculated Ctrl and Stk24 KO CT26 cells into immune‐competent BALB/c mice and administered continuous intraperitoneal injections of anti‐CD8α monoclonal neutralizing antibody (mAb) or anti‐immunoglobulin G (IgG) isotype control (IgG2β) during the tumorigenesis (Figure 3E). The gene discussed is CD8A; the disease is neoplasm.